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Performance of an automated human immunodeficiency virus (HIV) antigen/antibody combined assay for prenatal screening for HIV infection in pregnant women Fourth-generation antigen/antibody (Ag/Ab) combined assays, which allow the simultaneous detection of anti-human immunodeficiency virus (anti-HIV) antibodies and HIV p24 core protein in serum or plasma, are increasingly used for both the diagnosis of and screening for HIV infection. These assays have been shown to reduce the diagnostic window by a mean of 4 or 5 days compared with third-generation HIV-Ab detection assays (Weber et al., 1998) . Nevertheless, discrepant results have been published on their specificities in population groups with low prevalence of HIV infection, such as blood donors (Bourlet et al., 2005; Gürtler et al., 1998; Kwon et al., 2006; Ly et al., 2000 Ly et al., , 2004 Ly et al., , 2007 Sickinger et al., 2004; Weber et al., 1998 Weber et al., , 2002 . Prenatal screening for HIV infection is currently recommended to prevent vertical HIV transmission. Pregnancy has been recognized as a risk factor for false-positive results in HIV immunoassays (Celum et al., 1994; Doran & Parra, 2000; Magee et al., 1999; Zacharias et al., 2004) . In the present study we determined the rate of falsepositive results with a fourth-generation HIV Ag/Ab combined assay used for the routine prenatal screening for HIV infection and compared it to that of a third-generation HIV immunoassay. The sera giving false-positive results in the third-generation HIV Ab assay (n55) were retrieved and analysed by the HIV Ag/Ab combined assay. All these sera tested repeatedly positive (weakly reactive, S/CO ,3). Likewise, available sera (n520) of those yielding false-positive results in the HIV combined test were analysed by the AxSYM HIV 1/2/gO assay, and with an HIV p24-Ag-detection assay. Two sera tested positive in the former assay (S/CO 1.2 and 1.7). All sera tested negative in the latter test.
HIV Ag/Ab combined immunoassays may potentially yield a higher rate of falsepositive results than third-generation Ab assays, as the former combine two reactions of a different nature, which may require different cut-off thresholds for optimal specificity and sensitivity, in a single test. Data published a few years ago appeared to support this assumption (Gürtler et al., 1998; Ly et al., 2000; Weber et al., 1998) . Nevertheless, the specificity of recently marketed HIV combined assays has been reported to be comparable to that of third-generation immunoassays (Bourlet et al., 2005; Kwon et al., 2006; Ly et al., 2004 Ly et al., , 2007 Sickinger et al., 2004; Weber et al., 2002) . Pregnancy has been recognized as a risk factor for false-positive results in HIV immunoassays (Celum et al., 1994 , 1999; Zacharias et al., 2004) . Our data suggest that the Architect HIV Ag/Ab Combo test yields a higher rate of falsepositive results than the third-generation AxSYM HIV 1/2/gO immunoassay for pregnant women undergoing prenatal screening for HIV infection, a population group with a low prevalence of HIV infection. Whether or not this difference was statistically significant could not be appropriately addressed, as sera were not run in parallel for both tests. Further studies are thus needed to clarify this. In a comparable study (Fitzpatrick & Kaminski, 2006) , the AxSYM HIV Ag/Ab combined assay (equivalent to the Architect assay) was also shown to yield a higher rate of false-positive results than the AxSYM HIV 1/2/gO test. The cause of false-positive reactivities in the Architect HIV combined test is unclear. In most cases, however, a spurious reaction between the patients' sera with the test Ags could be ruled out, as the sera gave negative results in the thirdgeneration immunoassay, which employs a similar combination of HIV recombinant Ags and synthetic peptides. Most likely, a non-specific binding of an unknown serum component with the p24-specific mAb may account for the false-positive reactivities. The extent could not be confirmed though, as none of the sera were reactive in a p24 Ag-detection assay. Nevertheless, the epitope specificity of the anti-p24 mAbs in both assays may be different. Although most false-positive results in the HIV combined test gave S/COs ,3, and thus we were suspicious of them being false-positive results, the performance of complementary tests is required to rule out a current HIV infection. The need for additional testing results in the deferral of the delivery of the report, which may create uncertainty and anxiety for the woman and her family. 
